GRAPHIC OMITED] PROGEN INDUSTRIES LIMITED UNDERWRITING AGREEMENT SIGNED FOR PROGEN LISTED OPTIONS BRISBANE, AUSTRALIA MONDAY MAY 16, 2005 Progen Industries Limited (ASX: PGL, NASDAQ: PGLAF) today announced that it has signed an Underwriting Agreement...Underwriting Agreement • May 17th, 2005 • Progen Industries LTD • Medicinal chemicals & botanical products
BRISBANE, AUSTRALIA MONDAY MAY 16, 2005 Progen Industries Limited (ASX: PGL, NASDAQ: PGLAF) today announced that it has signed an Underwriting Agreement in relation to the ASX listed Options expiring on 31 May 2005 with Emerging Growth Capital Pty Limited, (eG Capital). Accordingly, and provided all conditions of the Underwriting Agreement are met, eG Capital will take up any shortfall that exists if any of the listed Options (ASX:PGLO) remain unexercised following the expiry date.
All Correspondence to: PROGEN INDUSTRIES LIMITED PO Box 2403 Toowong Queensland 4066 Australia Telephone: +61 7 3842 3333 Facsimile: +61 7 3720 9624 www.progen.com.au April 7, 2006 T. Justus Homburg 33 Anchorage Street Cleveland Qld 4163 Dear Justus,...Progen Industries LTD • December 22nd, 2006 • Medicinal chemicals & botanical products
PROGEN PHARMACEUTICALS LIMITED Ordinary Shares, no par value per share PLACEMENT AGENCY AGREEMENTSubscription Agreement • May 3rd, 2007 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • New York
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT IDENTIFIED BY *** HAVE BEEN OMITTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.” Licence...Agreement • December 12th, 2013 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • Queensland
AGREEMENT AND PLAN OF MERGER dated as of February 3, 2008 by and among PROGEN PHARMACEUTICALS LIMITED, PROGEN PHARMACEUTICALS, INC., CELLGATE, INC. and SPROUT CAPITAL IX, L.P., as RepresentativeAgreement and Plan of Merger • January 14th, 2009 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • Queensland
This AGREEMENT AND PLAN OF MERGER dated as of February 3, 2008 (this “Agreement”) is made and entered into by and among Progen Pharmaceuticals Limited, a company organized under the laws of Queensland, Australia (“Parent”), Progen Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Sub”), CellGate, Inc., a Delaware corporation (the “Company”), and SPROUT CAPITAL IX, L.P., a Delaware limited partnership (the “Representative”), solely with respect to Article II hereof and such other provisions hereof which specifically refer to such Representative.
6th June, 2001 LETTER OF INTENT - VARIATION OF LEASE Difran Pty Ltd ACN 010 251 493 (Landlord) Progen Industries Ltd ACN 010 975 612 (Tenant) Lease means the lease between the Landlord and the Tenant registered at the Department of Natural Resources...Progen Industries LTD • December 23rd, 2002 • Medicinal chemicals & botanical products
Lease means the lease between the Landlord and the Tenant registered at the Department of Natural Resources as Lease No. 702700236.
Underwriting Agreement Progen Pharmaceuticals Limited Emerging Growth Capital Pty Limited Bell Potter Securities LimitedUnderwriting Agreement • May 3rd, 2007 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • New South Wales
WARRANT AGENT AGREEMENTWarrant Agent Agreement • May 18th, 2007 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • Colorado
Progen Pharmaceuticals Limited, an Australia corporation (the “Company”), Computershare, Inc., a Delaware corporation, and its fully owned subsidiary Computershare Trust Company, N.A. a federally chartered trust company, having its principal office at 250 Royall Street, Canton, MA 02021 (collectively “Warrant Agent” or individually “Computershare” and the “Trust Company,” respectively), agree as follows:
ASA Termination AgreementProgen Pharmaceuticals LTD • December 18th, 2007 • Medicinal chemicals & botanical products • Queensland
Medigen Biotechnology Corporation, a company incorporated in Taiwan, of Building F, Room A, 14F., No.3, Yuancyu St., Nangang District, Taipei City 115, Taiwan
Exclusive Licence Agreement PharmaSynth Pty Ltd PharmaSynth Global Transbiotech Inc GTB Clayton Utz Lawyers Level 28 Riparian Plaza 71 Eagle Street Brisbane QLD 4000 Australia GPO Box 55 Brisbane QLD 4001 T + 61 7 3292 7000 F + 61 7 3221 9669...Licence Agreement • December 30th, 2009 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • California
Parties PharmaSynthPharmaSynth Pty Ltd, ABN 48 074 656 509, of 2806 Ipswich Road, Darra, QLD, Australia (“PharmaSynth”), a wholly-owned subsidiary of Progen Pharmaceuticals Ltd
Exclusive Licence & Collaboration Agreement Progen Pharmaceuticals Limited PGL Medigen Biotechnology Corp. MBC Clayton Utz Lawyers Level 28 Riparian Plaza 71 Eagle Street Brisbane QLD 4000 Australia GPO Box 55 Brisbane QLD 4001 T + 61 7 3292 7000 F +...Progen Pharmaceuticals LTD • January 21st, 2011 • Medicinal chemicals & botanical products • Queensland
Share sale and purchase agreementProgen Pharmaceuticals LTD • October 30th, 2015 • Medicinal chemicals & botanical products • Victoria
SUBSCRIPTION AGENT AGREEMENTSubscription Agent Agreement • May 18th, 2007 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • Massachusetts
This Subscription Agent Agreement (the “Agreement”) is made as of May 15, 2007 between Progen Pharmaceuticals Limited, an Australia Corporation (the “Company”), Computershare, Inc., a Delaware corporation and its fully owned subsidiary Computershare Trust Company, N.A., a federally chartered trust company (collectively, the “Agent” or individually “Computershare” and the “Trust Company,” respectively). All terms not defined herein shall have the meaning given in the prospectus dated April 13, 2007 and in the preliminary prospectus supplement dated May 10, 2007 (together, the “Prospectus”) included in the Registration Statement on Form F-3, File No. 333-141489 filed by the Company with the Securities and Exchange Commission on March 22, 2007, as amended by any amendment filed with respect thereto (the “Registration Statement”).
MASTER SERVICES AGREEMENTMaster Services Agreement • December 18th, 2007 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products
This Master Services Agreement (“Agreement”) is made between Progen Pharmaceuticals Limited ABN 82 010 975 612 which has a place of business 16 Benson Street, Toowong, Queensland 4066, Australia (hereinafter “Sponsor”), and Quintiles East Asia Pte Ltd a Singaproe corporation having its principal place of business at 89 Science Park Drive, Lobby B, #03-08 The Rutherford, Science Park One, Singapore 118261 (hereinafter “Quintiles”). When signed by both parties, this Agreement will set forth the terms and conditions under which Quintiles agrees to provide certain services to Sponsor as set forth herein.
